Erythropoietin: A candidate neuroprotective agent in the treatment of glaucoma

Journal of Glaucoma

Volumn 16, Issue 6, 2007, Pages 567-571

  Tsai, James C ^a   Song, Brian J ^b   Wu, Li ^b   Forbes, Max ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Erythropoietin; Glaucoma; Intravitreal injection; Neuroprotection

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ANEMIA; ANGIOGENESIS; ARTICLE; BLOOD VESSEL OCCLUSION; CANCER; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; MEDICAL LITERATURE; NEUROPROTECTION; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANIMALS; ERYTHROPOIETIN, RECOMBINANT; GLAUCOMA; HUMANS; INJECTIONS; NEUROPROTECTIVE AGENTS; VITREOUS BODY;

EID: 34548675154     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e318156a556     Document Type: Article

References (85)

1. Schwartz M. Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all? J Glaucoma. 2005;14:321-323.
2. Kerrigan LA, Zack DJ, Quigley HA, et al. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031-1035.
3. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma: the Beaver Dam Eye Study. Ophthalmology. 1992;99:1499-1504.
4. Okisaka S, Murakami A, Mizukawa A, et al. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn J Ophthalmol. 1997;41:84-88.
5. Quigley HA, Nickells RW, Kerrigan LA, et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774-786.
6. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull. 2004;62:455-459.
7. Bianchi R, Brines M, Lauria G, et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res. 2006;12:2607-2612.
8. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992;72:449-489.
9. Jelkmann W, Hellwig-Burgel T. Biology of erythropoietin. Adv Exp Med Biol. 2001;502:169-187.
10. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002;99:2258-2263.
11. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinent human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experiemental spinal cord trauma. Proc Natl Acad Sci USA. 2002;99:9450-9455.
12. Calvillo L, Latini R, Kajstura J, et al. Recombinent human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806.
13. Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2005;102:2046-2051.
14. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100:11612-11617.
15. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
16. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem. 2004;279:20655-20662.
17. Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA. 2004;101:823-828.
18. Agnello D, Bigini P, Villa P, et al. Erythropoietin exerts an antiinflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002;952:128-134.
19. Sattler MB, Merkler D, Maier K, et al. Neuroprotective effects and intracellular signaling pathways or erythropoietin in a rat model of multiple sclerosis. Cell Death Differ. 2004;11(suppl 2):S181-S192.
20. Savino C, Pedotti R, Baggi F, et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol. 2006;172:27-37.
21. Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry. 2004;9:42-54.
22. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526-10531.
23. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
24. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998;95:4635-4640.
25. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98:4044-4049.
26. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004;110:1006-1012.
27. Gong H, Wang W, Kwon TH, et al. EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int. 2004;66:683-695.
28. Nemoto T, Yokota N, Keane WF, et al. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001;59:246-251.
29. Patel NSA, Sharples EJ, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004;66:983-989.
30. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115-2124.
31. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19:348-355.
32. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17:1754-1755.
33. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002;8:718-724.
34. Junk A, Mammis A, Savitz S, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2002;99:10659-10664.
35. Kilic U, Kilic E, Soliz J, et al. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J. 2005;19:249-251.
36. Tsai JC, Wu L, Worgul B, et al. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res. 2005;30:1025-1031.
37. Weishaupt J, Rohde G, Pölking E, et al. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004;45:1514-1522.
38. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6:484-494.
39. Mulcahy L. The erythropoietin receptor. Semin Oncol. 2001;28(suppl 8):19-23.
40. Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol. 1998;5:171-176.
41. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006;70:246-250.
42. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab. 2002;22:503-514.
43. Zhuang H, Niu Z, He TC, et al. Erythropoietin-dependent inhibition of apoptosis is supported by carboxyl-truncated receptor forms and blocked by dominant-negative forms of Jak2. J Biol Chem. 1995;270:14500-14504.
44. Gobert S, Chretien S, Gouilleux F, et al. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. Embo J. 1996;15:2434-2441.
45. Miura O, Nakamura N, Ihle JN, et al. Erythropoietin-dependent association of phosphatidylinositol 3-kinase with tyrosine-phosphorylated erythropoietin receptor. J Biol Chem. 1994;269:614-620.
46. Reed JC. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med. 2001;7:314-319.
47. -/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999;98:181-191.
48. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20:2687-2695.
49. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab. 2003;23:320-330.
50. Murphy AN, Fiskum G. Bcl-2 and Ca(2+)-mediated mitochondrial dysfunction in neural cell death. Biochem Soc Symp. 1999;66:33-41.
51. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA. 1990;87:5978-5982.
52. Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA. 1995;92:3717-3720.
53. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey, and murine brain. Eur J Neurosci. 1996;8:666-676.
54. Masuda S, Okano M, Yamagishi K, et al. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493.
55. Ogilvie M, Yu X, Nicolas-Metral V, et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem. 2000;275:39754-39761.
56. Siren AL, Knerlich F, Poser W, et al. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276.
57. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999;19:643-651.
58. Campana WM, Misasi R, O'Brien JS. Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med. 1998;1:235-241.
59. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signaling is required for normal brain development. Development. 2002;129:505-516.
60. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci. 2004;22:105-119.
61. Dawson TM. Preconditioning-mediated neuroprotection through erythropoietin? Lancet. 2002;359:96-97.
62. Prass K, Scharff A, Ruscher K, et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke. 2003;34:1981-1986.
63. Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.
64. Grasso G, Sfacteria A, Cerami A, et al. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist. 2004;10:93-98.
65. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101:14907-14912.
66. Xenocostas A, Cheung W, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol. 2005;61:189-195.
67. Banks W, Jumbe N, Farrell C, et al. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol. 2004;505:93-101.
68. Tsai JC, Hwang DH, Wu L, et al. Retinal function assessment following intravitreal injection of erythropoietin in rats: a dose-toxicity study. Invest Ophthalmol Vis Sci. 2006;47:E-abstract 5724.
69. Package insert. Epogen (Epoetin Alfa). Thousand Oaks, CA: Amgen; July 1999.
70. Buckner FS, Eschbach JW, Haley NR, et al. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens. 1990;3:947-955.
71. Lim VS. Recombinent human erythropoietin in predialysis patients. Am J Kidney Dis. 1991;18:34-37.
72. Nowicki M. Erythropoietin and hypertension. J Hum Hypertens. 1995;9:81-88.
73. Varet B, Casadevall N, Lacombe C, et al. Erythropoietin: physiology and clinical experience. Semin Hematol. 1990;27:25-31.
74. Dai C, Chung IJ, Krantz SB. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp Hematol. 2005;33:152-158.
75. Aguilera A, Selgas R, Ruiz-Caravaca ML, et al. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients. Perit Dial Int. 1999;19(suppl 2):S161-S166.
76. Ando M, Iwata A, Ozeki Y, et al. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 2002;62:1757-1763.
77. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-2989.
78. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
79. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305:239-242.
80. Coleman TR, Westenfelder C, Togel FE, et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA. 2006;103:5965-5970.
81. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA. 2003;100:6741-6746.
82. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Visual Sci. 2007;48:1212-1218.
83. King CE, Rodger J, Bartlett C, et al. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol. 2007;205:48-55.
84. Fu QL, Wu W, Wang H, et al. Up-regulated endogenous erythropoietin/ erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol. 2007. [Epub ahead of print].
85. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol. 2006;18:132-138.